Showing 2,405 news articles about HIV treatment

Filters Content type: Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

New & experimental HIV treatments

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Editor's pick
ViiV Healthcare press release
13 January 2020
Weight gain & lipodystrophy

What we know about Descovy’s impact on weight & cholesterol

Editor's pick
San Francisco AIDS Foundation
9 January 2020
Starting treatment

New Yorkers are initiating treatment earlier after HIV infection, study shows

Editor's pick
EurekAlert
8 January 2020
The search for a cure

Does timing matter for initiating HIV therapy in infants?

Editor's pick
EurekAlert
8 January 2020
Drug interactions & pharmacokinetics

How to Check Illicit Drug Interactions With Hep C Medications

Editor's pick
Filter
7 January 2020
Pregnancy and vertical transmission

South Africa steps up its game to end mother-to-child transmission of HIV

Editor's pick
The Conversation
7 January 2020
Bad science & bogus treatments

Facebook disables some misleading ads on HIV prevention drugs, responding to growing outcry

Editor's pick
Washington Post
2 January 2020
Injectable & long-acting HIV treatment

No holiday gift for GSK: FDA sends long-acting HIV injectable back to work

Editor's pick
FiercePharma
24 December 2019
Injectable & long-acting HIV treatment

FDA Defers Approval of First Long-Acting HIV Therapy, Surprising Everyone

Editor's pick
HIV and ID Observations
23 December 2019
Treatment guidelines

What's New in the Guidelines?

Editor's pick
AIDSinfo
19 December 2019
Pregnancy and vertical transmission

US: Prescribing practices for pregnant women with HIV not aligned with guidelines

Editor's pick
Healio
19 December 2019
New & experimental HIV treatments

CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV

Editor's pick
CytoDyn press release
18 December 2019
New & experimental HIV treatments

Capsid inhibitor GS-6207: potential for 6 monthly dosing for MDR HIV

Editor's pick
i-Base
16 December 2019
Drug-resistant TB

WHO Recommends Worldwide Adoption Of All Oral-Regimen For MDR/RR-TB

Editor's pick
Health Policy Watch
16 December 2019
PrEP science

Facebook ads push misinformation about HIV prevention drugs, LGBT activists say, ‘harming public health’

Editor's pick
Washington Post
10 December 2019
Resistance

WHO unveils plan to tackle rising HIV drug resistance in Africa

Editor's pick
World Health Organization
9 December 2019
Pharmaceutical industry

Gilead delayed safer HIV drug to extend monopoly profits, advocates allege

Editor's pick
San Francisco Chronicle
6 December 2019
New & experimental HIV treatments

ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Editor's pick
5 December 2019
Bad science & bogus treatments

China’s CRISPR babies: Read exclusive excerpts from the unseen original research

Editor's pick
MIT Technology Review
4 December 2019
Weight gain & lipodystrophy

New Formulation of Tesamorelin Available for HIV Patients With Lipodystrophy

Editor's pick
Infectious Disease Advisor
4 December 2019
HIV treatment

Top 10 HIV Clinical Developments of 2019

Editor's pick
TheBodyPro
27 November 2019
Government, leadership & policy

The World Cannot End HIV Without Continued Innovation

Editor's pick
POZ
25 November 2019
Changing treatment

Caveat emptor: Seven things every patient should know about switching from efavirenz to dolutegravir

Editor's pick
Spotlight
25 November 2019
New & experimental HIV treatments

ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational "bNAb" with potential for long-acting HIV treatment and prevention

Editor's pick
ViiV Healthcare press release
21 November 2019